← Back to Screener
Kezar Life Sciences, Inc. Common Stock (KZR)
Price$7.29
Favorite Metrics
Price vs S&P 500 (26W)64.95%
Price vs S&P 500 (4W)4.50%
Market Capitalization$53.74M
All Metrics
Book Value / Share (Quarterly)$9.56
P/TBV (Annual)0.25x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-7.06
Price vs S&P 500 (YTD)12.40%
Net Profit Margin (TTM)-1254.16%
EPS (TTM)$-7.66
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-7.66
EPS (Annual)$-7.66
ROI (Annual)-79.96%
Cash / Share (Quarterly)$9.80
ROA (Last FY)-73.11%
EBITD / Share (TTM)$-7.96
ROE (5Y Avg)-51.78%
Operating Margin (TTM)-1383.84%
Cash Flow / Share (Annual)$-7.06
P/B Ratio0.77x
P/B Ratio (Quarterly)0.66x
Net Income / Employee (Annual)$-1
ROA (TTM)-54.83%
EPS Incl Extra (Annual)$-7.66
Current Ratio (Annual)11.52x
Quick Ratio (Quarterly)11.34x
3-Month Avg Trading Volume0.06M
52-Week Price Return80.54%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.97
P/S Ratio (Annual)7.68x
Asset Turnover (Annual)0.03x
52-Week High$7.55
EPS Excl Extra (Annual)$-7.66
CapEx CAGR (5Y)-46.93%
Tangible BV CAGR (5Y)38.88%
26-Week Price Return73.70%
Quick Ratio (Annual)11.34x
13-Week Price Return18.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.52x
Enterprise Value$-18.14
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)25.77%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1455.29%
Cash / Share (Annual)$9.80
3-Month Return Std Dev48.33%
Net Income / Employee (TTM)$-1
ROE (Last FY)-79.96%
EPS Basic Excl Extra (Annual)$-7.66
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-7.66
ROI (TTM)-60.32%
P/S Ratio (TTM)9.50x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.94
Price vs S&P 500 (52W)45.45%
Year-to-Date Return16.53%
5-Day Price Return-1.35%
EPS Normalized (Annual)$-7.66
ROA (5Y Avg)-44.98%
Net Profit Margin (Annual)-1455.29%
Month-to-Date Return-1.21%
Cash Flow / Share (TTM)$-1.20
EBITD / Share (Annual)$-7.96
Operating Margin (Annual)-1591.77%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-49.63%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-7.66
P/TBV (Quarterly)0.31x
P/B Ratio (Annual)0.66x
Pretax Margin (TTM)-1254.16%
Book Value / Share (Annual)$9.56
Price vs S&P 500 (13W)15.94%
Beta0.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-64.42%
52-Week Low$3.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.50
3.50
3.50
3.50
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KZRKezar Life Sciences, Inc. Common Stock | 9.50x | — | — | — | $7.29 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Kezar Life Sciences is a clinical-stage biotechnology company developing small molecule therapeutics for autoimmunity and cancer indications. The company's pipeline includes lead candidates Zetomipzomib (KZR-616) and KZR-261, designed to address significant unmet medical needs in these therapeutic areas.